Bioventix CFO Increases Stake Through Share Purchase

An update from Bioventix ( (GB:BVXP) ) is now available.

Bioventix plc announced that its Chief Financial Officer, Bruce Hiscock, purchased 31 ordinary shares of the company at an average price of 2,632 pence per share through a dividend reinvestment plan. This transaction, which increases Hiscock’s beneficial interest to 1,205 ordinary shares, represents approximately 0.02% of the company’s issued share capital and is disclosed in compliance with the EU Market Abuse Regulation.

Spark’s Take on GB:BVXP Stock

According to Spark, TipRanks’ AI Analyst, GB:BVXP is a Outperform.

Bioventix is in a strong financial position with excellent profitability and a robust balance sheet. Despite technical pressure, its fair valuation and high dividend yield provide a compelling investment case. Recent corporate events further bolster confidence in its growth potential.

To see Spark’s full report on GB:BVXP stock, click here.

More about Bioventix

Bioventix plc is a UK-based company that specializes in the development and commercial supply of high-affinity monoclonal antibodies for clinical diagnostics applications.

YTD Price Performance: -16.05%

Average Trading Volume: 8,198

Technical Sentiment Signal: Buy

Current Market Cap: £135.3M

See more data about BVXP stock on TipRanks’ Stock Analysis page.